BurningRock OncoScreen PlusTM Report
19-Nov-2019 is an internal database of Burning Rock Dx with reference to public ... inhibitor (Navurizumab plus Ipilimumab) regardless of their PD-L1 ...
get supplementary file.php?f=
Burning Rock Biotech Limited
core products including OncoScreen Plus™ and LungPlasma™
776P SHR-1701 a bifunctional fusion protein targeting PD-L1 and
a 520-gene panel (OncoScreen Plus Burning Rock Biotech) to identify genetic alter- ations that might be associated with treatment response in 39 pts.
HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired
520 cancer-related genes (OncoScreen Plus; Burning Rock. Biotech Guangzhou
777P A prospective single-arm
https://www.annalsofoncology.org/article/S0923-7534(21)03448-7/pdf
775P Tremelimumab (T) + durvalumab (D) combined with
a 520-gene panel (OncoScreen Plus Burning Rock Biotech) to identify genetic alter- ations that might be associated with treatment response in 39 pts.
Figures and Tables
Burning Rock DX OncoScreen Plus. ST25†/ST26/ST27/ST28. 1631. 523 hg19. 100. IDT. Integrated DNA Technologies xGen Pan-Cancer Panel ST04/ST05/ST06.
Cross oncopanelstudyreveals supp ?sequence= &isAllowed=y
Distinctive genomic characteristics in POLE/POLD1-mutant cancers
(Burning Rock Guangzhou
PB R
The clinical efficacy of combinatorial therapy of EGFR-TKI and
sisting of either 520 cancer-related genes (OncoScreen Plus) or 168 lung Plasma) and 520-gene panel (OncoScreen Plus) Burning Rock Biotech).
Distinctive genomic characteristics in POLE/POLD1-mutant cancers
(Burning Rock Guangzhou